Galinpepimut-S is a subunit vaccine commercialized by SELLAS Life Sciences Group, with a leading Phase III program in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to Globaldata, it is involved in 14 clinical trials, of which 9 were completed, and 5 are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Galinpepimut-S’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Galinpepimut-S is expected to reach an annual total of $169 mn by 2038 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Galinpepimut-S Overview

Galinpepimut-S is under development for the treatment of acute myelocytic leukemia (AML), acute lymphocytic leukemia (ALL),  lung cancer, solid tumor, malignant pleural mesothelioma, multiple myeloma, ovarian cancer, colorectal cancer, triple-negative breast cancer, small-cell lung cancer, fallopian tube or primary peritoneal cancer, ovarian cancer, fallopian tube cancer, peritoneal cancer, diffuse large B-cell lymphoma, follicular lymphoma, pediatric tumors and myelodysplastic syndrome. It is formulated as an emulsion or solution and administered subcutaneously and parenterally. It is a synthetic peptide vaccine consisting of the immunogenic amino acids of the human Wilms tumor protein-1 peptides which include WT-1 A1, WT-1 122 long, WT-1 427 long and WT-1 331 long. The therapeutic candidate targets Wilms tumor protein 1 (WT1). It was also under development for the treatment of chronic myeloid leukemia (CML) and glioblastoma multiforme.

SELLAS Life Sciences Group Overview

SELLAS Life Sciences Group (SELLAS) is a clinical biopharmaceutical company. Its products include GFH009, a highly selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor and galinpepimut-S. Galinpepimut-S (GPS), a cancer immunotherapeutic drug that targets Wilms tumour 1, is in Phase 3 clinical studies for the treatment of acute myeloid leukaemia and in Phase 1/2 clinical trials for the treatment of ovarian cancer. The company collaborates with Memorial Sloan Kettering Cancer Center (MSKCC), National Cancer Institute (NCI) and The University of Texas M.D. Anderson Cancer Center (MDACC) for conducting clinical trials targeting multiple cancer indications. SELLAS is headquartered in New York City, New York, the US.
The company reported revenues of (US Dollars) US$1 million for the fiscal year ended December 2022 (FY2022), a decrease of 86.8% over FY2021. The operating loss of the company was US$42 million in FY2022, compared to an operating loss of US$25.3 million in FY2021. The net loss of the company was US$41.3 million in FY2022, compared to a net loss of US$20.7 million in FY2021.

For a complete picture of Galinpepimut-S’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.